Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab

Journal of Neuro-Oncology

Volumn 125, Issue 2, 2015, Pages 445-446

  Essayed, W I ^a,c   Bernard, A ^b   Kalamarides, M ^a,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b La Rochelle Re Aunis Hospital ^*  (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR;

ADULT; BRAIN TUMOR; CANCER RECURRENCE; CASE REPORT; CENTRAL NERVOUS SYSTEM; CERVICOMEDULLARY EPENDYMOMA; EPENDYMOMA; FEMALE; GENE; GENE FUSION; GENE MUTATION; HUMAN; LETTER; NEURILEMOMA; NF2 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; SPINAL CORD EPENDYMOMA; TREATMENT RESPONSE; TUMOR GROWTH; VOCAL CORD PARALYSIS; COMPLICATION; NEUROFIBROMATOSIS 2; RADIOGRAPHY; SPINAL CORD NEOPLASMS;

ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; EPENDYMOMA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROFIBROMATOSIS 2; SPINAL CORD NEOPLASMS;

EID: 84945450880     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1925-8     Document Type: Letter

References (4)

1. Green RM, Cloughesy TF, Stupp R et al (2009) Bevacizumab for recurrent ependymoma. Neurology 73:1677–1680
2. Parker M, Mohankumar KM, Punchihewa C et al (2014) C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 506:451–455
3. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367
4. Nunes FP, Merker VL, Jennings D et al (2013) Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS one 8:e59941